What this is
- How it works
- How it works isn't classified yet
- Tested for
- Aggressive Behavior in Fragile X Syndome
- Main trialPhase 2
- “The goal of this clinical trial is to learn if drug SRX246 works to treat irritability, agitation, aggression and self-injury (IAAS) behaviors in adult males with Fragile X Syndrome (FXS). It will also learn about the safety of drug SRX246. The main questions it aims to answer are: * Does drug SRX246 lower the number of times participants experience IAAS behaviors? * What medical problems do participants have when taking drug SRX246? Researchers will compare drug SRX246 to a placebo (a look-alike substance that contains no drug) to see if drug SRX246 works to treat IAAS behaviors.…”In the company’s words, NCT07328529 on ClinicalTrials.gov
Other drugs for Aggressive Behavior in Fragile X Syndome
- ZatolmilastTetra Discovery Partners · Phase 3
- CodabakalnerSpinogenix · Phase 2/3
- ZYN002Harmony Biosciences · Phase 2/3
- CTH120Connecta Therapeutics, S.L. · Phase 2
- MRM-3379Mirum Pharmaceuticals, Inc. · Phase 2
- S247240Institut de Recherches Internationales Servier (I.R.I.S.) · Phase 2
Coming up1
- Dec 2027Phase 2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials4
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Not yet recruiting | Dec 2027 | Inhibition of Aggressive Behavior in Participants With Fragile X Syndrome | |
| Phase 2Completed | 10 Sep 2018 | Tolerability, Safety, and Activity of SRX246 in Irritable Subjects With Huntington's Disease | |
| Phase 2Terminated | Oct 2020 | Proof-of-concept Study to Assess the Efficacy and Safety of SRX246 in Adults With PTSD | |
| Phase 1/2Completed | May 2016 | Safety, Tolerability and Activity of SRX246 in Adults With Intermittent Explosive Disorder |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026